Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
FLT3/AXL Inhibitor (A... 2020.06.22  
  1. "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

    Date2018-06-03 MediaBusinesswire PipelineLazertinib
    Read More
  2. Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

    Date2018-05-16 MediaBusinesswire PipelineLazertinib
    Read More
  3. More than half of Korean biopharma firms view R&D investments as assets.

    Date2018-03-14 MediaThe Korea Herald PipelineIndustry
    Read More
  4. Oscotec shares rebound on launch of US clinical trial

    Date2017-12-11 MediaKBR (; Korea Biomedical Review) PipelineSKI-G-801
    Read More
  5. INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

    Date2016-08-23 MediaScrip (Informa Pharma Intelligence) PipelineOscotec
    Read More
  6. Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

    Date2016-01-19 MediaScrip (Informa Pharma Intelligence) PipelineSYK-O-703
    Read More
  7. G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

    Date2014-04-03 MediaPubMed PipelineSKI-G-801
    Read More
  8. Profiles of Four New Stock-Billionaires

    Date2007-02-19 MediaMBN PipelineOscotec
    Read More
  9. IPOs spawn instant billionaires

    Date2007-02-20 MediaThe Korea Herald PipelineOscotec
    Read More
Board Pagination Prev 1 2 Next
/ 2
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.